Chinese Journal of Antituberculosis ›› 2014, Vol. 36 ›› Issue (11): 958-965.doi: 10.3969/j.issn.1000-6621.2014.11.008
Previous Articles Next Articles
CHENG Song, LI Yuan-yuan, HU Zhong-yi, CUI Zhen-ling
Received:2014-06-18
Online:2014-11-10
Published:2014-12-05
Contact:
CUI Zhen-ling
E-mail:cuizhenling@163.com
CHENG Song, LI Yuan-yuan, HU Zhong-yi, CUI Zhen-ling. The diagnostic value of PCR-DNA sequencing for the rapid detection of ethambutol-resistance in Mycobacterium tuberculosis: a Meta-analysis[J]. Chinese Journal of Antituberculosis, 2014, 36(11): 958-965. doi: 10.3969/j.issn.1000-6621.2014.11.008
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2014.11.008
| [1]World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11.Geneva: World Health Organization,2013.[2]Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb), 2010, 90(3):162-167.[3]World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization,2009.[4]刘宇红,姜广路,赵立平,等. 第四次全国结核病流行病学抽样调查——结核分枝杆菌耐药性分析与评价. 中华结核和呼吸杂志, 2002,25(4):224-227.[5]全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8): 485-508.[6]Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinb), 2007,87(2):123-129.[7]Jadaun GP, Das R, Upadhyay P, et al. Role of embCAB gene mutations in ethambutol resistance in Mycobacterium tuberculosis isolates from India. Int J Antimicrob Agents, 2009, 33(5):483-486.[8]Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536.[9]Devillé WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol, 2002,2:9.[10]Zamora J, Abraira V, Muriel A, et al. Meta-Disc: a software for meta-analysis of test accuracy data. BMC Med Res Me-thodol, 2006,6:31.[11]Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg, 2005, 79 (1):16-20.[12]俞慧强, 郑辉烈, 李悦, 等. Meta 分析发表偏倚诊断方法研究. 中国卫生统计, 2011, 28(4): 402-405.[13]Escalante P, Ramaswamy S, Sanabria H, et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis,1998,79(2):111-118.[14]Ramaswamy SV, Amin AG, Goksel S, et al. Molecular gene-tic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2000, 44(2): 326-336.[15]Lee AS, Othman SN, Ho YM, et al. Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents Chemother, 2004, 48(11): 4447-4449.[16]Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-KopecE, et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol, 2007, 45(1): 179-192.[17]Perdigao J, Macedo R, Ribeiro A, et al. Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Int J Antimicrob Agents, 2009,33(4):334-338.[18]Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother,2011,55(5):2032-2041.[19]张楠, 胡继红, 万康林. 乙胺丁醇耐药表型与耐药基因embB突变的关系. 中国卫生检验杂志,2010,20(3):490-492.[20]Brossier F, Veziris N, Aubry A, et al. Detection by Geno Type MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol,2010,48(5): 1683-1689.[21]Hazbón MH, Bobadilla del Valle M, Guerrero MI, et al. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother, 2005,49(9):3794-3802.[22]Zhang SL, Qi H, Qiu DL, et al. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates recovered from central China. Biochem Genet,2007, 45(3-4):281-290.[23]Guo JH, Xiang WL, Zhao QR, et al. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Sichuan Province in China. Jpn J Infect Dis, 2008,61(4):264-268.[24]Plinke C, Cox HS, Kalon S, et al. Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis (Edinb), 2009, 89(6):448-452.[25]Hu Y, Hoffner S, Jiang W, et al. Genetic characterisation of drug-resistant Mycobacterium tuberculosis in rural China: a population-based study. Int J Tuberc Lung Dis, 2010,14(2):210-216.[26]Shi D, Li L, Zhao Y, et al. Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother,2011,66(10):2240-2247.[27]Huang WL, Chi TL, Wu MH, et al. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol,2011,49(7):2502-2508.[28]林辉.重庆市结核病耐药的流行病学调查及耐药相关基因分子特征研究.重庆:第三军医大学,2008.[29]Hillemann D,Rüsch-Gerdes S,Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol,2009, 47(6): 1767-1772.[30]Miotto P, Cabibbe AM, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J, 2012,40(3): 690-698.[31]郭琪,李觉,胡忠义,等. 焦磷酸测序技术检测结核分枝杆菌异烟肼耐药性的Meta分析.中华检验医学杂志,2013,36(4):329-332.[32]Plinke C, Rüsch-Gerdes S, Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resis-tance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2006,50(5):1900-1902.[33]Parsons LM, Salfinger M, Clobridge A, et al. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol.Antimicrob Agents Chemother,2005,49(6):2218-2225.[34]Xu HB, Jiang RH, Sha W, et al. PCR-single-strand conformational polymorphism method for rapid detection of rifampin-resistant Mycobacterium tuberculosis: Systematic review and meta-analysis. J Clin Microbiol, 2010, 48(10):3635-3640. |
| [1] | Song Feier, Mao Yanjun, Xia Qiuyue, Zhou Yang, Lin Huan. The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 322-330. |
| [2] | Shi Yilin, Gu Yan. Meta-analysis of the efficacy, adverse reactions, and fatality rate of glucocorticoid combined with anti-tuberculosis drugs in the treatment of tuberculous serositis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 77-86. |
| [3] | Wu Jinfeng, Yang Zhen, Zhang Fuzhen, Yao Cong. Meta-analysis of the diagnostic value of oral swab for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 815-822. |
| [4] | Zheng Rui, Zhao Mingrui, Yang Yuanzheng. Meta-analysis of effectiveness and safety of the cycloserine-containing treatment for multidrug-resistant pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2023, 45(7): 658-668. |
| [5] | Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926. |
| [6] | YU Chun-hong, LIU Xing, SHEN Ling-jun, LI Hai-wen, LI Xie, WU Rong-shuang, LI Xian-rui, FAN Hao. Meta analysis of efficacy and safety of the treatment containing bedaquiline for multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 660-668. |
| [7] | Li Shuolan, Li Mingwu, Li Guangmei, Wang Lin, Wan Rong, Ma Meng. Influencing factors of getting unfavorable treatment outcomes of patients with multidrug-resistant pulmonary tuberculosis in China: a Meta-analysis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1303-1313. |
| [8] | Muradil·Mardan , Parhat·Yasin , Xu Tao, Cai Xiaoyu, Yakup·Abliz , Xun Chuanhui, Sheng Weibin, Mardan·Mamat . Meta-analysis of operation combined with irrigation and drainage of focus lesion in the treatment of spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1314-1320. |
| [9] | Wang Yajuan, Cao Xinyi, Liu Shengming. Meta-analysis of the diagnostic value of metagenomic next-generation sequencing and GeneXpert MTB/RIF in tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1327-1337. |
| [10] | An Huiru, Han Yiran, Yan Mengdie, Wu Xueqiong. Meta-analysis on clinical effectiveness of combination regimens with interferon-γ in treatment of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(10): 1002-1009. |
| [11] | CHEN Wen, YAO Li, CHEN Kang, DAI Xi-yong. Meta-analysis on the diagnostic value of metagenomic next-generation sequencing on cerebrospinal fluid for detecting tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1066-1072. |
| [12] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
| [13] | HUANG Guo-jun, GAO Yuan, TANG Xi-liang, GAO Xiao, BAI Li-qiong. Efficacy and safety of thymopentin in adjuvant treatment of retreatment positive pulmonary tuberculosis: a Meta-analysis [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 570-577. |
| [14] | MA Gai-xia,TIAN Li-ming,WANG Yu,QIU Lei,XUE Ling-na,LU Zhen-hui,ZHANG Hui-yong,GUO Xiao-yan. Systematic evaluation and meta-analysis of integrated traditional Chinese and western medicine in the treatment of MDR-PTB [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 95-100. |
| [15] | Jin-hong XU,Song YANG,Li-xin ZHANG,Ying ZHONG,Qian QIU. Risk factors of multidrug-resistant tuberculosis in China: A meta-analysis [J]. Chinese Journal of Antituberculosis, 2019, 41(12): 1301-1309. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.